TARPEYO®/Kinpeygo® (developed under the project name Nefecon®) is a second-generation, synthetic, non-halogenated form of the corticosteroid budesonide. The delayed release formulation of budesonide has shown greater efficacy for protein reduction and slowing the decline in kidney function in primary immunoglobulin A (IgA) as well as a much better safety profile than conventional corticosteroids. As such, it will likely experience high uptake for high-risk patients.
Calliditas Therapeutics AB has partnered with STADA Arzneimittel AG to commercialize Kinpeygo in Europe and with Everest Medicines to commercialize TARPEYO in Mainland China, Hong Kong, Macau, Taiwan, South Korea and Singapore.
With its modified targeted drug release technology, this second-generation synthetic nonhalogenated form of budesonide provides superior safety and efficacy compared with first-generation corticosteroids. The 4-mg delayed-release capsule is enteric-coated so it remains intact until it reaches the ileum where it targets the mucosal B cells, including Peyer’s patches, responsible for the IgA-causing complexes. Because of the absorption characteristics, it may result in fewer side effects than other corticosteroids despite prolonged use.
Submissions for regulatory approval have been based on data from the phase 3, placebo-controlled NefIgArd clinical trial. The study was conducted with adult patients with primary IgA nephropathy who were at risk of progressing to end-stage renal disease (ESRD) despite maximum tolerated treatment with optimized renin-angiotensin system (RAS) blockade. Budesonide treatment lasted nine months, followed by a 15-month observational follow-up period off the study drug. The results demonstrated slowed progression of IgA nephropathy with budesonide:
November 2016
November 2020
December 2021
July 2022
November 2022
February 2023
For adult patients with IgA neuropathy at risk of rapid disease progression (UPCR ≥1.5 g/g)
June 2023
August 2023
September 2023
October 2023
December 2023
Actual and expected launch:
Patents estimated to expire beginning in 2028
How will budesonide impact the market for IgA nephropathy/Berger’s disease?
What gaps in treatment does budesonide fill?
IgA nephropathy is a rare, progressive kidney disorder that can lead to end-stage renal disease requiring dialysis or a kidney transplant. IgA nephropathy generally progresses slowly, and treatment is primarily directed at managing symptoms, minimizing kidney failure and improving patient quality of life through multidisciplinary supportive care. Clinicians are looking for a more holistic approach that takes into account all of these aims (i.e., reduce protein levels and improve kidney function and therefore quality of life). Therefore, effective, safe and well-tolerated drugs that protect kidney function or slow the progressive decline in GFR are needed. Because of its better efficacy and safety, budesonide will likely provide physicians with an alternative option to conventional corticosteroids.
What hurdles might it need to overcome to reach blockbuster status?
The extremely high price of TARPEYO/Kinpeygo will likely constrain its use, especially since nephrologists are reluctant to prescribe expensive therapies unless they are shown to be significantly more effective. In addition, other potential competitors that specifically treat IgA nephropathy have already been approved or are in late-stage development, which could make it a crowded market.
– Source: Cortellis Competitive Intelligence, Drug Timeline & Success Rates Prediction current as of December 15, 2023
Access global intelligence, advanced analytics and global experts from Clarivate.